Isoptin

Verapamil hydrochloride, the active ingredient in Isoptin, is a calcium channel blocker presented as an oral tablet for oral use. It is used to treat hypertension, angina pectoris, and certain cardiac arrhythmias in adult patients by inhibiting L‑type calcium channels, which reduces myocardial contractility, heart rate, and peripheral vascular resistance.\n\nGNH India supplies Isoptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoptin is a calcium channel blocker that acts on the cardiovascular system to manage several related conditions.\n\nHypertension: lowers elevated blood pressure by reducing peripheral vascular resistance.\nAngina pectoris: relieves chest pain by decreasing myocardial oxygen demand.\nSupraventricular tachycardia: controls rapid heart rhythms by slowing conduction through the AV node.

Isoptin may cause a range of adverse reactions, from mild to serious.\n\nCommon Side Effects:\n- Dizziness\n- Headache\n- Constipation\n- Flushing\n- Peripheral edema\n- Nausea\n\nSerious or Rare Side Effects:\n- Severe bradycardia\n- Heart block or AV conduction disturbances\n- Marked hypotension\n- Hepatic dysfunction\n- Allergic reactions such as rash or anaphylaxis\n- Exacerbation of heart failure

Before initiating therapy with Isoptin, consider the following safety measures.\n\nMonitor blood pressure: ensure adequate control and watch for hypotension.\nAssess cardiac function: evaluate for existing conduction abnormalities or heart failure.\nReview concomitant beta‑blocker use: combined effect may cause excessive bradycardia.\nAdjust dose in hepatic impairment: reduced metabolism may increase drug exposure.\nAvoid in patients with severe AV block without a pacemaker.\nStore at room temperature: keep in the original container, protect from moisture.

Verapamil interacts with several medicines that can alter its efficacy or safety.\n\nMajor Interactions (Avoid):\n- Beta‑blockers: risk of profound bradycardia.\n- Digoxin: increased serum levels leading to toxicity.\n- Diltiazem: additive AV‑node depression.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): elevate verapamil concentrations.\n- St. John’s wort: may reduce therapeutic effect.\n\nModerate Interactions (Monitor Closely):\n- Diuretics: electrolyte shifts can affect cardiac response.\n- Antacids: may decrease absorption if taken simultaneously.\n- Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy.\n- Quinidine: may raise verapamil levels modestly.\n- Rifampin: can lower verapamil concentrations.